1. Home
  2. BGLC vs MRKR Comparison

BGLC vs MRKR Comparison

Compare BGLC & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BGLC
  • MRKR
  • Stock Information
  • Founded
  • BGLC 2017
  • MRKR N/A
  • Country
  • BGLC Malaysia
  • MRKR United States
  • Employees
  • BGLC N/A
  • MRKR N/A
  • Industry
  • BGLC Medical Specialities
  • MRKR Biotechnology: Pharmaceutical Preparations
  • Sector
  • BGLC Health Care
  • MRKR Health Care
  • Exchange
  • BGLC Nasdaq
  • MRKR Nasdaq
  • Market Cap
  • BGLC 10.4M
  • MRKR 11.6M
  • IPO Year
  • BGLC N/A
  • MRKR N/A
  • Fundamental
  • Price
  • BGLC $5.53
  • MRKR $1.08
  • Analyst Decision
  • BGLC
  • MRKR Strong Buy
  • Analyst Count
  • BGLC 0
  • MRKR 3
  • Target Price
  • BGLC N/A
  • MRKR $13.17
  • AVG Volume (30 Days)
  • BGLC 178.0K
  • MRKR 312.6K
  • Earning Date
  • BGLC 11-14-2025
  • MRKR 11-13-2025
  • Dividend Yield
  • BGLC N/A
  • MRKR N/A
  • EPS Growth
  • BGLC N/A
  • MRKR N/A
  • EPS
  • BGLC N/A
  • MRKR N/A
  • Revenue
  • BGLC $9,551,559.00
  • MRKR $5,388,071.00
  • Revenue This Year
  • BGLC N/A
  • MRKR N/A
  • Revenue Next Year
  • BGLC N/A
  • MRKR $9.35
  • P/E Ratio
  • BGLC N/A
  • MRKR N/A
  • Revenue Growth
  • BGLC 4.01
  • MRKR 44.55
  • 52 Week Low
  • BGLC $2.01
  • MRKR $0.81
  • 52 Week High
  • BGLC $15.60
  • MRKR $5.95
  • Technical
  • Relative Strength Index (RSI)
  • BGLC 47.38
  • MRKR 54.04
  • Support Level
  • BGLC $5.19
  • MRKR $0.85
  • Resistance Level
  • BGLC $5.47
  • MRKR $1.13
  • Average True Range (ATR)
  • BGLC 0.33
  • MRKR 0.07
  • MACD
  • BGLC -0.04
  • MRKR 0.03
  • Stochastic Oscillator
  • BGLC 11.17
  • MRKR 64.29

About BGLC BioNexus Gene Lab Corp Common stock

BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

Share on Social Networks: